With the advancement of the drug-enhanced tumor-infiltrating lymphocyte (DeTIL) therapy platform, Nurix has developed the ex vivo Cbl-b inhibitor NX-0255 to be administered with adoptive T cell therapy. The gene discussed is CBLB; the disease is neoplasm.